Strategic Expansion Neuland is expanding its manufacturing footprint in Hyderabad with a new 135,000 sq ft facility and dedicated process development labs, signaling increased capacity for complex API and NCE production—a prime opportunity for scalable CDMO collaborations and longer-term outsourcing partnerships.

Sterile API Growth Recent partnership with Gland Pharma to expand sterile API manufacturing presents a doorway to cross-sell sterile and complex API capabilities to pharma and biotech companies seeking robust, integrated CDMO support across development to commercial stages.

Financial Momentum Strong quarterly revenues and rising profitability, including a record quarter and double-digit profit growth, underscore financial health and reliability for clients seeking a financially stable partner for multi-year development and manufacturing programs.

End-to-End CDMO Neuland’s end-to-end services from early development to commercial supply, including process development, optimization, analytical testing, regulatory compliance, and tech transfer, position it as a one-stop shop for clients aiming to streamline timelines and de-risk scale-up.

CPP and PK/PD Support Ongoing CPP development for PK/PD studies and Phase I formulations opens opportunities to engage with biotech and pharma customers pursuing translational studies, especially in biosimilar or novel therapeutic programs requiring robust PK/PD data generation.